<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38113577</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-5353</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Respiratory investigation</Title><ISOAbbreviation>Respir Investig</ISOAbbreviation></Journal><ArticleTitle>Clinical features of pneumothorax associated with COVID-19: A retrospective analysis of two centres.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>141</EndPage><MedlinePgn>137-141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resinv.2023.12.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2212-5345(23)00103-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pneumothorax is a known sequela of coronavirus disease 2019 (COVID-19). However, the clinical features of pneumothorax associated with COVID-19 have not been fully elucidated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients who developed pneumothorax within 6 months of being diagnosed with COVID-19 were retrospectively analysed at two institutions. We investigated the background factors, COVID-19 severity and treatment, timing of pneumothorax onset, treatment modalities, treatment duration, and prognosis of these patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 21 patients were diagnosed with pneumothorax within 6 months of COVID-19 diagnosis. The combined incidence rate of pneumothorax at two institutions was 0.89&#xa0;%. The mean age of these patients was 72.5 years, and they were predominantly male (90.5&#xa0;%), with a history of smoking (76.1&#xa0;%). The most frequent comorbidity was hypertension, followed by type 2 diabetes mellitus, COPD, and malignancy. Approximately 76&#xa0;% of the patients had moderate or severe disease requiring oxygenation. Moreover, 90.5&#xa0;% of these patients were taking antiviral drugs; 52.4&#xa0;%, immunosuppressant agents (baricitinib/tocilizumab); and 66.7&#xa0;% were on dexamethasone. The median time to the onset of pneumothorax was 15.0 days, and 86&#xa0;% of cases occurred within 1 month of COVID-19 diagnosis. Bilateral pneumothorax and pneumomediastinum were noted in one patient each. Chest drainage was performed in 71.4&#xa0;% of the patients. The mean treatment duration for pneumothorax was 14.1 days, and the 30-day mortality rate was 28.6&#xa0;%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pneumothorax associated with COVID-19 was more common in patients with moderate or severe disease requiring oxygenation, and occurred within 1 month of COVID-19 diagnosis. Pneumothorax associated with COVID-19 is a serious complication with a high mortality rate and clinicians should pay attention to it.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; Department of Infectious Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. Electronic address: kfujita.acd@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanai</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; Department of Infectious Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hata</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; Department of Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imakita</LastName><ForeName>Takuma</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oi</LastName><ForeName>Issei</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odagaki</LastName><ForeName>Takao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoyama</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Kyoto Katsura Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawai</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mio</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Respir Investig</MedlineTA><NlmUniqueID>101581124</NlmUniqueID><ISSNLinking>2212-5345</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011030" MajorTopicYN="Y">Pneumothorax</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chest drainage</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Pneumothorax</Keyword></KeywordList><CoiStatement>Declaration of competing interest KF received research funding from AstraZeneca and Merck &amp; Co., Inc, these are not directly related to this study. Other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38113577</ArticleId><ArticleId IdType="doi">10.1016/j.resinv.2023.12.001</ArticleId><ArticleId IdType="pii">S2212-5345(23)00103-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>